Integrin α6/ITGA6/CD49f Antibody (4F10): sc-53356

Integrin α6 Antibody (4F10) is a mouse monoclonal IgG2b kappa light chain antibody raised against the SW1222 human colorectal cell line, designed to detect Integrin α6 from mouse, rat, and human origins by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Integrin α6, also known as ITGA6 or CD49f, is a transmembrane glycoprotein that pairs with β subunits, particularly β1 and β4, to form heterodimers essential for cell adhesion to the extracellular matrix through laminin binding. Integrin α6 undergoes crucial post-translational modifications such as glycosylation and phosphorylation, which are vital for proper folding, stability, and functional activity in signal transduction pathways. Glycosylation affects the ligand-binding capacity and cell-surface expression of Integrin α6, while phosphorylation of its cytoplasmic domain modulates interactions with intracellular signaling molecules and proteins involved in linking Integrin α6 to the actin cytoskeleton, influencing processes like cell migration, proliferation, and survival. Dysregulation or aberrant modification of Integrin α6 has been associated with various pathological conditions, including cancer progression and metastasis, underscoring the importance of studying these modifications. Anti-Integrin α6 antibody (4F10) is available in non-conjugated form and serves as a valuable tool for researchers investigating the role of Integrin α6 in cellular adhesion, signaling pathways, and disease mechanisms. By providing accurate detection across multiple species, Integrin α6 monoclonal antibody (4F10) aids in advancing our understanding of Integrin α6 function and its impact on health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Integrin α6/ITGA6/CD49f Antibody (4F10) References:

1. RNA interference targeting human integrin α6 suppresses the metastasis potential of hepatocellular carcinoma cells.  |  Lv, G., et al. 2013. Eur J Med Res. 18: 52. PMID: 24304619
2. Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy.  |  Hu, T., et al. 2016. Sci Rep. 6: 33376. PMID: 27624978
3. Regulation of Integrin α6 Recycling by Calcium-independent Phospholipase A2 (iPLA2) to Promote Microglia Chemotaxis on Laminin.  |  Lee, SH., et al. 2016. J Biol Chem. 291: 23645-23653. PMID: 27655917
4. Integrin alpha6 maintains the structural integrity of the kidney collecting system.  |  Viquez, OM., et al. 2017. Matrix Biol. 57-58: 244-257. PMID: 28043890
5. Elevated integrin α6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics.  |  Shen, J., et al. 2019. J Cancer Res Clin Oncol. 145: 1681-1693. PMID: 31175464
6. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.  |  Gang, EJ., et al. 2020. Blood. 136: 210-223. PMID: 32219444
7. Mesenchymal Stem Cell-Derived Exosomal microRNA-3940-5p Inhibits Colorectal Cancer Metastasis by Targeting Integrin α6.  |  Li, T., et al. 2021. Dig Dis Sci. 66: 1916-1927. PMID: 32671583
8. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer.  |  Gao, S., et al. 2020. Signal Transduct Target Ther. 5: 147. PMID: 32782265
9. Integrin α6 overexpression promotes lymphangiogenesis and lymphatic metastasis via activating the NF-κB signaling pathway in lung adenocarcinoma.  |  Ren, S., et al. 2022. Cell Oncol (Dordr). 45: 57-67. PMID: 35025009
10. Integrin alpha6 is involved in follicular growth in mice.  |  Nakamura, K., et al. 1997. Biochem Biophys Res Commun. 235: 524-8. PMID: 9207189

The preferred Integrin α6/ITGA6/CD49f antibody is Integrin α6/ITGA6/CD49f Antibody (GOH3): sc-19622.